| Patients (n) randomized to anti-hypertensive treatment |
Male/Female (n)
|
Dosage (daily)
|
Baseline seated BP (mmHg) |
Seated SBP/Seated DBP reduction (mmHg) |
% achieved BP target
|
Study Reference |
| 502
|
280/222
|
Placebo
OM 40 mg
HCTZ 25 mg
OM/HCTZ 40/25 mg |
152.1/103.4
152.9/102.6
155.9/104.4
153.6/103.4 |
3.3/8.2
16.0/14.6
17.1/12.9
26.8/21.9 |
SeSBP<140 mmHg
33.3
60
67.4
87.2 |
[6] |
| 1870
|
1143/727
|
OM/HCTZ 20/12.5 mg
OM/HCTZ 20/25 mg
OM/HCTZ 40/12,5 mg
OM/HCTZ 40/25 mg |
155.8/97.2
153.3/96.8
154.1/97.6
153.9/97.3 |
11.6/8.0
17.2/10.5
13.9/9.2
17.3/11.2 |
NE
|
[7] |
| 278
|
63/74
|
Placebo
OM/HCTZ 40/25 mg
|
155.3/93.7
156.9/94.2
|
0.1/+0.8
22.3/12.1
|
SeBP< 140/90 mmHg
30.7
74.1 |
[9] |
| 191
|
102/89
|
Benazepril/ amlodipine
20/10 mg
OM/HCTZ 40/25 mg |
169.6/101.4
167.0/101.7 |
26.5/N.R.
32.5/N.R. |
SeBP<140/90 mmHg
44.7
66.3 |
[11] |
| 972
|
599/373
|
OM/HCTZ 40/25 mg
|
155.4/98.0
|
30.3/19.0
|
SeBP<140/90 mmHg
(<130/80 mmHg for T2DM)
42.1 |
[12] |
| 176 |
92/84 |
OM/HCTZ 40/25 mg |
165.5/87.7 |
25.4/10.5 |
SeBP<140/90 mmHg
67 |
[14] |
